Evidence map›Paper›PMID 37957644›Full record

ArticleBMC cancer2023

Survival of cervical cancer patients at Moi teaching and Referral Hospital, Eldoret in western Kenya.

E Mwaliko, P Itsura, A Keter, Dirk De Bacquer, N Buziba, H Bastiaens, A Jackie, A Obala, V Naanyu, P Gichangi and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

E MwalikoDepartment of Reproductive Health, School of Medicine, Moi University, Box 4606, Eldoret, 30100, Kenya. waleghwaem@hotmail.com.
P ItsuraDepartment of Reproductive Health, Gyn-Oncology Group, School of Medicine, Moi University, Box 4606, Eldoret, 30100, Kenya.
A KeterUSAID AMPATH, Moi Teaching and Referral Hospital, Eldoret, Kenya.
Dirk De BacquerDepartment of Public Health and Primary Care, Ghent University, Gent, Belgium.
N BuzibaDepartment of Pathology, School of Medicine/Head, Registry, Moi, Eldoret Cancer , University, Box 4606, Eldoret, 30100, Kenya.
H BastiaensDepartment of Primary and Interdisciplinary Care, Faculty of Medicine and Health Sciences, University of Antwerp, Gouverneur Kinsbergen Centrum, Doornstraat 331, Wilrijk, 2610, Antwerp, Belgium.
A JackieSBT Population Health AMPATH, P.O. Box 4606, Eldoret, Kenya.
A ObalaDepartment of Microbiology, Health Sciences Project-VLIR-Moi University Project, P.O. Box 3900, Eldoret, 30100, Kenya.
V NaanyuDVC Academic Research & Extension, Technical University of Mombasa/Visiting Professor, Ghent University, Gent, Belgium.
P GichangiDepartment of Sociology Psychology and Anthropology, School of Arts and Social Sciences, Moi University, P.O. Box 3900, Eldoret, 30100, Kenya.
M TemmermanDepartment of Public Health and Primary Care, Ghent University, Gent, Belgium.
Moi University · KEAMPATH · KEGhent University · BETechnical University of Mombasa · KEUniversity of Antwerp · BEUniversity of Eldoret · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCervical cancer is a major health burden and the second most common cancer after breast cancer among women in Kenya. Worldwide cervical cancer constitutes 3.1% of all cancer cases. Mortality rates are greatest among the low-income countries because of lack of awareness, screening and early-detection programs and adequate treatment facilities. The main aim was to estimate survival and determine survival predictors of women with cervical cancer and limited resources in western Kenya.

methodsRetrospective charts review of women diagnosed with cervical cancer and follow-up for two years from the date of the histologic diagnosis. The outcome of interest was death or survival at two years. Kaplan Meier estimates of survival, log-rank test and Cox proportional hazards regression were used in the survival analysis.

resultsOne hundred and sixty-two (162) participants were included in the review. The median duration was 0.8 (interquartile range (IQR) 0.3, 1.6) years. The mean age at diagnosis was 50.6 years (SD12.5). The mean parity was 5.9 (SD 2.6). Fifty percent (50%) did not have health insurance. Twenty six percent (26%) used hormonal contraceptives, 25.9% were HIV positive and 70% of them were on anti-retroviral treatment. The participants were followed up for 152.6 person years. Of the 162 women in the study, 70 (43.2%) died giving an overall incidence rate (IR) of 45.9 deaths per 100 person years of follow up. The hazard ratios were better for the patients who survived (0.44 vs 0.88, p-value < 0.001), those who had medical insurance (0.70 vs 0.48, p-value = 0.007) and those with early stage at diagnosis (0.88 vs 0.39, p-value < 0.001). Participants who were diagnosed at late stage of the disease according to the International Federation of Gynecology and Obstetrics staging for cervical cancer (FIGO stage 2B-4B) had more than eight times increased hazard of death compared to those who were diagnosed at early stage (1-2A): Hazard Ratio: 8.01 (95% CI 3.65, 17.57). Similarly, those who underwent surgical management had 84% reduced hazard of mortality compared to those who were referred for other modes of care: HR: 0.16 (95% CI: 0.07, 0.38).

conclusionMajority of the participants were diagnosed late after presenting with symptoms. The 1 and 2-year survival probability after diagnosis of cervical cancer was 57% AND 45% respectively. It is imperative that women present early since surgery gives better prognosis or better still screening of all women prioritized.

Indexed as

Uterine Cervical NeoplasmsFemaleHospitalsHumansKenyaMiddle AgedNeoplasm StagingReferral and ConsultationRetrospective StudiesCervical cancerKenyaSurvival

Identifiers

PMID37957644
PMCPMC10644535
OpenAlexW4388627340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.